Recent patents in allergy and immunology: The interleukin‐2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases
Allergy · 2024
DOI: 10.1111/all.16271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2024. Verfasst von Christie Fanton und 1 weiteren Autor:innen. Beteiligte Einrichtung: Nektar Therapeutics, San Francisco, California, USA. Hauptthemen laut MEDLINE: Autoimmune Diseases, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nektar Therapeutics, San Francisco, California, USA.
Zitieren
APA
Fanton, C., & Zalevsky, J. (2024). Recent patents in allergy and immunology: The interleukin‐2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases. Allergy. https://doi.org/10.1111/all.16271
Vancouver
Fanton C, Zalevsky J. Recent patents in allergy and immunology: The interleukin‐2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases. Allergy. 2024. doi:10.1111/all.16271
BibTeX
@article{Fanton2024,
author = {Fanton, Christie and Zalevsky, Jonathan},
title = {Recent patents in allergy and immunology: The interleukin‐2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases},
journal = {Allergy},
year = {2024},
doi = {10.1111/all.16271}
}
EUVIMED